A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
about
microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.Cytokine-induced interleukin-1 receptor antagonist protein expression in genetically engineered equine mesenchymal stem cells for osteoarthritis treatment.Tissue engineering of skin and regenerative medicine for wound care
P2860
A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
@en
type
label
A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
@en
prefLabel
A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
@en
P2093
P2860
P356
P1476
A Guide to Approaching Regulatory Considerations for Lentiviral-Mediated Gene Therapies.
@en
P2093
Carolina Gándara
Elizabeth A Stoll
Michael White
P2860
P304
P356
10.1089/HGTB.2017.096
P577
2017-08-01T00:00:00Z